看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。; s! }2 X; j; e" J$ p3 d3 s
6 l2 ~6 W9 S5 |1 }1 y
# h' t3 n5 E0 ~% M3 G8 eCurrently available feasibility data for possible combination strategies. ' Q/ e( E/ k( Y3 N
————————————————————————————————
/ Q6 j9 ~+ _$ V- D" I9 ]8 QCombination Feasibility according to preliminary data % q& E8 a" O0 s3 y7 ?
——————————————————————————————————
0 t% \% j! |0 F+ u2 OBevacizumab + sorafenib Yes, reduced dose " q3 y7 {4 J0 w8 {- t( G5 }
Bevacizumab + sunitinib† No
5 v1 ?0 J3 L; M6 S: pBevacizumab + temsirolimus Yes
. H4 v/ z! s: C4 Z' h9 vBevacizumab + everolimus Yes " D8 ?6 Y# |& D; [' h/ _
Sorafenib + sunitinib ? ' z3 J! a- ?9 p
Sorafenib + temsirolimus Yes, reduced dose 5 U$ F" } @8 T( m
Sorafenib + everolimus Yes, reduced dose
' g$ K$ ]( [) b @; E* \5 a0 JSunitinib + temsirolimus† No - _3 E4 p6 A9 E6 B$ F( ^+ m
Sunitinib + everolimus ? ; X. v% p a& j
Temsirolimus + everolimus ? 1 z2 }1 O" S% \0 G4 N" J
————————————————————
" |! O" ?; L$ y9 C! M( R& `4 f& G†Led to US FDA warning., y8 K- i( c F9 y0 ^& S. f
?: As yet unattempted combination." i0 N2 D" H! ^2 C
|
显身卡
